Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data

About this update from Myriad Genetics, Inc.

[{"type":"image","alt":"Myriad Genetics, Inc.","displaySize":"","headline":null,"caption":"Myriad Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_y5LWpbQjZzzOJzKUH_nTg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/d43f1e89209f6724a2684841f43efbbf","width":300,"height":138}},"lazy":false},{"type":"text","content":"Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026","length":94,"tagName":"p"},{"type":"text","content":"SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types.","length":403,"tagName":"p"},{"type":"text","content":"Myriad will launch Precise MRD with select community-based clinicians in March 2026 in breast, followed by colorectal and renal cancers later this year. The company may expand into additional cancer types, including ovarian and endometrial in 2027 and beyond.","length":259,"tagName":"p"},{"type":"text","content":"“Our Precise MRD program reflects Myriad’s unwavering commitment to advancing precision oncology by bringing ultrasensitive MRD testing into real-world clinical care,” said Sam Raha, President and CEO, Myriad Genetics. “By detecting ctDNA at extremely low levels and demonstrating a clear link to clinical outcomes, this limited clinical launch represents meaningful progress toward earlier insight, more informed decisions, and better outcomes for patients.”","length":459,"tagName":"p"},{"type":"text","content":"This timeline reflects the clinical evidence demonstrating Precise MRD’s high sensitivity and ability to detect ctDNA down to one part-per-million (ppm). Interim study analyses have suggested near-universal baseline detection and recurrence prediction in colorectal cancer, as well as high baseline sensitivity in breast cancer.","length":328,"tagName":"p"},{"type":"text","content":"The growing bo...

More updates from Myriad Genetics, Inc.